⌕
Ideaya Biosciences · IDYA · Nasdaq
Tenet 57 · Mixed
Compare
$30.36−4.62%At closeTenet 57 · Mixed
$30.36−1.47 (−4.62%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Ideaya Biosciences (IDYA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● PRNewsWireNov 16, 2026 · 16:05 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint Randomized Phase 3 trial in multiple refractory NEC subtypes…

● Seeking AlphaNov 16, 2026 · 10:53 ET
IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcript

IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcript…

● PRNewsWireNov 15, 2026 · 15:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5 inhi…

● PRNewsWireNov 4, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events

SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announce…

● Zacks Investment ResearchNov 3, 2026 · 08:26 ET
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to earnings of $1.33 per share a year ago.…

● PRNewsWireNov 3, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disease, irrespective of …

● PRNewsWireOct 30, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeu…

● Zacks Investment ResearchOct 27, 2026 · 11:01 ET
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● Defense WorldOct 27, 2026 · 05:11 ET
IDEAYA Biosciences (NASDAQ:IDYA) Shares Cross Below 200 Day Moving Average – Should You Sell?

IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $34.19 and traded as low as $32.52. IDE…

● PRNewsWireOct 23, 2026 · 06:00 ET
IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5% (55/101) cORR in 2L + ≥…

● PRNewsWireOct 19, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of HLA-A*02:01 allele status or …

● Defense WorldOct 11, 2026 · 05:38 ET
IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock

IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) CEO Yujiro Hata sold 26,338 shares of IDEAYA Biosciences stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of…

● Defense WorldSep 30, 2026 · 06:41 ET
IDEAYA Biosciences (NASDAQ:IDYA) Stock Jumps 4.8% – Here’s What Happened

IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report)'s stock price traded up 4.8% on Monday. The company traded as high as $38.38 and last traded at $38.45. Approximately 278,808 shares traded hands during trading, …

● PRNewsWireSep 28, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announ…

● PRNewsWireSep 25, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announ…

● Defense WorldSep 18, 2026 · 04:34 ET
Squarepoint Ops LLC Has $940,000 Holdings in IDEAYA Biosciences, Inc. $IDYA

Squarepoint Ops LLC reduced its holdings in IDEAYA Biosciences, Inc. (NASDAQ: IDYA) by 74.6% during a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm ow…

● Seeking AlphaSep 10, 2026 · 17:37 ET
IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

● PRNewsWireSep 9, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

Global Phase 3 trial will evaluate the darovasertib and crizotinib combination in primary uveal melanoma patients with increased risk of metastasis following completion of local therapy OptimUM-11 expands development of …

● PRNewsWireSep 1, 2026 · 06:00 ET
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announc…

● PRNewsWireAug 31, 2026 · 06:00 ET
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

Based on FDA Type C meeting, targeting to initiate a randomized Phase 3 registrational trial for IDE849 monotherapy by year-end 2026 in ES-SCLC, with ORR by BICR as the primary endpoint for potential accelerated approval…

● GuruFocusAug 28, 2026 · 07:00 ET
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISC…

● Seeking AlphaAug 25, 2026 · 09:13 ET
Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform

IDEAYA Biosciences is transitioning into a commercial oncology platform, leveraging darovasertib's registrational success and a robust internal pipeline. Darovasertib's phase 2 trial showed a median PFS of 6.9 vs. 3.1 mo…

● PRNewsWireAug 19, 2026 · 06:00 ET
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, Genentech's Phase 1 KRAS G12D inhibitor, in MTAP-dele…

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just IDYA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.